论文部分内容阅读
目的 :探讨12 5I组织间植入疗法疗效及其毒副作用。方法 :对 39例各种恶性肿瘤病人实施手术根治术后 ,术中同时将一定数量的12 5I粒子按一定间距排布植入特定部位的组织内。术前、术中、术后分别在一定位置使用γ数字辐射仪对植入粒子工作人员和病人进行照射量率的监测。术后结合病人情况实施相应的化疗 ,术前、术后不同时间测定病人血清免疫学指标 (IgA、IgG、IgM、C3、C4、B、C -RP)和外周血白细胞。结果 :术后随访期 (1周～ 16个月 )内 ,患者无异常症候群发生 ,未见相关放射病及其并发症的发生也无12 5I粒子脱落或排出体外事件发生。经X线、ECT、CT、B超检查无一例发现复发灶或新的转移灶。ECT扫描结果提示 ,粒子植入部位放射性分布均匀。血清免疫学指标和外周血白细胞检查 ,术后第 3周各项指标 ,均有不同程度的降低 ,但经方差分析统计学处理 ,无显著性差异 (P >0 .0 5 )。结论 :肿瘤12 5I粒子术中组织间永久植入疗法简便、安全、疗效显著、毒副作用极小 ,可单独实施也可与其他疗法综合应用。病人易接受 ,值得推广应用。
Objective: To investigate the curative effect and side effects of 125I interstitial implantation therapy. Methods: Thirty-nine patients with various malignant tumors underwent radical operation. At the same time, a certain number of 125I particles were implanted into the tissue of a specific site at certain intervals. Preoperative, intraoperative and postoperative were in a certain position using γ digital radiometer on implanted particle staff and patients were monitoring the dose rate. According to the patient’s condition, the corresponding chemotherapy, preoperative and postoperative serum immunological parameters (IgA, IgG, IgM, C3, C4, B, C -RP) and peripheral blood leukocytes were measured. Results: During the follow-up period (from 1 week to 16 months), there were no abnormalities in the patients. No incidence of radiological diseases and complications occurred or no 125I particles were shed or excreted. The X-ray, ECT, CT, B-ultrasound found no case of recurrent or new metastases. ECT scan results suggest that the particle implantation site radioactive distribution. Serum immunological indexes and peripheral blood leukocytes examination showed no significant difference (all P> 0.05) in the third week after operation. CONCLUSION: The permanent implantation therapy of 125I seeds in the operation of the tumor is simple and safe, with significant curative effect and minimal toxic and side effects. It can be used alone or in combination with other therapies. Patients are easy to accept, it is worth promoting application.